AveXis Inc (NASDAQ:AVXS) has received an average recommendation of “Buy” from the twenty-two brokerages that are currently covering the firm, MarketBeat reports. Four analysts have rated the stock with a sell rating, two have given a hold rating and sixteen have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $125.50.
A number of equities research analysts have recently weighed in on the stock. BidaskClub upgraded shares of AveXis from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Sanford C. Bernstein reiterated an “outperform” rating and issued a $144.00 price target (up from $110.00) on shares of AveXis in a research report on Tuesday, February 20th. Mizuho set a $147.00 price objective on shares of AveXis and gave the company a “buy” rating in a research report on Wednesday, March 14th. Zacks Investment Research downgraded shares of AveXis from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Chardan Capital restated a “buy” rating and set a $135.00 price objective on shares of AveXis in a research report on Friday, January 5th.
AVXS stock traded down $0.01 during midday trading on Friday, hitting $124.96. 274,043 shares of the stock were exchanged, compared to its average volume of 403,264. AveXis has a 52 week low of $65.23 and a 52 week high of $138.46. The firm has a market capitalization of $4,589.57, a P/E ratio of -17.33 and a beta of 2.02.
In other AveXis news, insider Brian K. Kaspar sold 15,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $109.75, for a total transaction of $1,646,250.00. Following the sale, the insider now owns 1,808,386 shares of the company’s stock, valued at $198,470,363.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Sean P. Nolan sold 10,000 shares of the business’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $129.47, for a total transaction of $1,294,700.00. Following the sale, the chief executive officer now directly owns 10,000 shares in the company, valued at approximately $1,294,700. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 65,560 shares of company stock worth $7,793,030. Insiders own 18.60% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC grew its stake in shares of AveXis by 52.2% during the third quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock worth $99,363,000 after buying an additional 352,456 shares during the last quarter. Perceptive Advisors LLC grew its stake in shares of AveXis by 147.5% during the third quarter. Perceptive Advisors LLC now owns 671,181 shares of the company’s stock worth $64,923,000 after buying an additional 400,000 shares during the last quarter. Westfield Capital Management Co. LP bought a new stake in shares of AveXis during the third quarter worth $39,563,000. Eagle Asset Management Inc. grew its stake in shares of AveXis by 123.4% during the fourth quarter. Eagle Asset Management Inc. now owns 354,154 shares of the company’s stock worth $39,274,000 after buying an additional 195,626 shares during the last quarter. Finally, Deutsche Bank AG grew its stake in shares of AveXis by 42.7% during the fourth quarter. Deutsche Bank AG now owns 303,901 shares of the company’s stock worth $33,630,000 after buying an additional 90,934 shares during the last quarter. 82.43% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “AveXis Inc (AVXS) Given Average Recommendation of “Buy” by Brokerages” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3296326/avexis-inc-avxs-given-average-recommendation-of-buy-by-brokerages.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.